# A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

> **NCT04168190** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 600 (actual)

## Conditions studied

- Pneumonia, Pneumococcal

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** Pneumovax™23

## Key facts

- **NCT ID:** NCT04168190
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-06
- **Primary completion:** 2021-07-12
- **Final completion:** 2021-07-12
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04168190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04168190, "A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04168190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*